思力华联合舒利迭对稳定期中重度慢性阻塞性肺疾病的疗效

发布时间：2019-01-27 19:17

【摘要】：目的观察思力华联合舒利迭治疗稳定期中重度慢性阻塞性肺疾病(COPD)的效果。方法确诊稳定期中重度COPD患者40例随机均分为两组,常规止咳平喘治疗基础上,A组加用思力华和舒利迭治疗:思力华每日1次,每次1吸;舒利迭每日2次,每次1吸。B组仅加用舒利迭。记录治疗前、治疗1个月和3个月时的圣乔治问卷调查表(SGRQ)评分;测定治疗前和治疗3个月后血清IL-32浓度。结果两组治疗后的SGRQ评分均较治疗前减少(P0.01)。A组和B组治疗3个月后的血清IL-32表达均比治疗前降低[(60.5±13.5)ng/L vs.(70.2±13.5)ng/L和(61.3±12.5)ng/L vs.(70.5±14.1)ng/L](P0.05)。两组治疗期间均未见明显不良反应。结论在常规止咳平喘治疗基础上,应用舒利迭或思力华和舒利迭联用均能改善稳定期中重度COPD患者的临床症状和生活质量,降低患者血清IL-32表达水平。
[Abstract]:Objective to observe the effect of treatment of moderate and severe chronic obstructive pulmonary disease (COPD) by combination of silva and sulidide. Methods 40 patients with moderate and severe COPD in stable period were randomly divided into two groups. On the basis of routine antitussive and antiasthmatic therapy, group A was treated with srivastatin and sulidide: once a day, 1 inhalation per time; Schlide was inhaled 2 times a day. The (SGRQ) scores of St George's questionnaire before treatment, 1 month and 3 months after treatment were recorded, and serum IL-32 levels were measured before and 3 months after treatment. Results the SGRQ scores of the two groups after treatment were lower than those before treatment (P0.01). A and B groups after 3 months of treatment, the expression of serum IL-32 was lower than that before treatment [(60.5 卤13.5) ng/L vs. (70.2 卤13.5)] Ng/L and (61.3 卤12.5) ng/L vs. (70.5 卤14.1) ng/L] (P0.05). There was no obvious adverse reaction during treatment in both groups. Conclusion on the basis of routine antitussive and antiasthmatic therapy, the combination of sultidide or sillide and sulipid can improve the clinical symptoms and quality of life of patients with moderate and severe COPD, and decrease the level of serum IL-32 expression in patients with moderate and severe COPD.
【作者单位】：南京医科大学附属无锡市人民医院呼吸病科;
【分类号】：R563.9

【相似文献】